The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label trial of SMK treatment of advanced metastatic cancer.
Steve Hoffman
No relevant relationships to disclose
Howard Bruckner
No relevant relationships to disclose
Giuseppe Del Priore
Consultant or Advisory Role - Luminent BioScience
Daniel Gurell
No relevant relationships to disclose
Ruslan Mull
No relevant relationships to disclose
Damian Stega
No relevant relationships to disclose
Gail Goodwin
No relevant relationships to disclose
Mike Demurjian
No relevant relationships to disclose
Jeanetta Malanowska-Stega
No relevant relationships to disclose